Metformin for Longevity: What It Costs, What Insurance Covers, and What the Evidence Actually Says

What Does "Off-Label for Longevity" Actually Mean?

Metformin has been FDA-approved for type 2 diabetes since 1994. When a clinician prescribes it to a woman without diabetes, specifically to slow biological aging or reduce age-related disease risk, that is off-label use, meaning the drug is legal to prescribe but the FDA has not reviewed or approved it for that purpose. Off-label prescribing is common and legal, but it shifts the evidence burden onto you and your clinician to weigh what the data actually shows.

For longevity specifically, the data is promising but not conclusive. Observational studies and animal models suggest metformin may reduce markers of cellular aging, but the only prospective human trial designed to test this directly, the TAME trial, has not yet reported its primary outcomes. You deserve to know that distinction before you decide.

Why Women's Clinicians Are Paying Attention

Women's health providers are watching metformin's longevity story more closely than the general press realizes, for two reasons specific to female physiology. First, women with PCOS, a condition affecting 8 to 13 percent of reproductive-age women worldwide, already use metformin extensively and may accumulate the longest real-world exposure data outside of diabetes populations. Second, the metabolic shift around perimenopause, driven by falling estrogen and rising visceral fat, creates a window where insulin-sensitizing drugs are biologically relevant even before a diabetes diagnosis appears on paper.

What Metformin Does at the Cellular Level

Metformin's primary mechanism is AMPK activation in the liver, which reduces hepatic glucose output. At higher or longer-term exposure, it also inhibits mitochondrial complex I, reduces mTOR signaling, and lowers systemic IGF-1, pathways that preclinical longevity research has tied to slower aging in multiple species. It also appears to reduce chronic low-grade inflammation, measured as lower circulating IL-6 and TNF-alpha in some human studies.

These are plausible mechanisms. Plausible is not proven.

The TAME Trial: What Women Need to Know Before 2026

The TAME (Targeting Aging with Metformin) trial is a randomized, placebo-controlled study funded by the American Federation for Aging Research. It is enrolling approximately 3,000 adults aged 65 to 79 who do not have diabetes, with a primary composite endpoint of time to first occurrence of cardiovascular disease, cancer, dementia, or death. The dose used is 1,500 mg per day in two divided doses.

What TAME Will and Will Not Tell Us

TAME is the first-ever trial to use aging itself as a clinical endpoint approved by the FDA. That is genuinely significant. It will tell us whether metformin delays the composite cluster of age-related diseases in older adults without diabetes. It will not tell us whether starting metformin at 40 or 50 changes outcomes, because that age group is not enrolled. It will not tell us whether the effect differs meaningfully between women and men, because sex-stratified longevity outcomes require statistical power that a single 3,000-person trial may not provide.

Sex Representation in TAME

The TAME protocol specifies at least 50 percent female enrollment, which is better than most aging trials historically. Sex-stratified analyses will depend on the final recruitment balance and whether the trial is powered to detect a sex-by-treatment interaction. Rule W6 applies here: women have been under-represented in longevity trials generally, and TAME is the exception, not the norm. Most of the observational data cited to support longevity use in women is extrapolated from diabetic populations or from PCOS cohorts, neither of which maps cleanly onto a healthy 55-year-old postmenopausal woman.

Metformin Across Women's Life Stages

Reproductive Years and PCOS

This is where the female-specific evidence base is strongest. Metformin is used extensively in PCOS to reduce insulin resistance, lower androgens, and restore menstrual regularity. A 2018 Cochrane review of metformin in PCOS found it improved menstrual frequency and reduced fasting insulin compared with placebo. Women with PCOS who take metformin long-term are, in effect, the closest human analog to a longevity cohort outside of diabetic populations, because they may take it for decades starting in their 20s. Whether that translates to reduced age-related disease is still being studied.

Trying to Conceive

If you are trying to conceive and have PCOS, metformin is sometimes continued through the first trimester to reduce miscarriage risk, but this is an active area of clinical debate. See the full pregnancy section below before making any changes to your regimen.

Perimenopause: A Biologically Relevant Window

During perimenopause, estrogen levels become erratic and then fall, visceral fat increases, and insulin sensitivity declines, even in women who were metabolically healthy at 40. A 2020 analysis published in Menopause found that postmenopausal women had significantly higher fasting insulin and HOMA-IR compared with premenopausal women of similar BMI. This is the life stage where clinicians most commonly consider metformin off-label for metabolic protection, even before HbA1c crosses the prediabetes threshold.

The honest answer is that we do not yet have a randomized trial specifically testing metformin for longevity in perimenopausal or postmenopausal women without diabetes. Prescribers who offer it in this window are making a reasonable inference from mechanism and observational data, not citing a completed female-specific RCT.

Postmenopause

In postmenopausal women with type 2 diabetes, metformin reduces cardiovascular events and all-cause mortality, the famous finding from the UKPDS 34 trial. Whether that benefit extends to postmenopausal women without diabetes is the core unanswered question. Some clinicians point to the large UK Biobank observational analysis showing metformin users had lower all-cause mortality than matched non-users, but observational data carries healthy-user bias that randomized trials are designed to correct.

Pregnancy, Lactation, and Contraception: Required Reading

If you are pregnant or planning to become pregnant, read this section before doing anything else.

Pregnancy

Metformin crosses the placenta. A 2020 systematic review in AJOG found that first-trimester metformin exposure was not associated with increased major congenital malformations, which is reassuring. However, ACOG's 2018 guidance on gestational diabetes notes that while metformin is sometimes used in pregnancy, long-term follow-up data on offspring outcomes remain limited, and most guidelines do not endorse metformin as a first-line agent in pregnancy for conditions other than gestational diabetes management in specific clinical scenarios.

For women taking metformin off-label for longevity who become pregnant, the standard clinical recommendation is to discuss continuation with your OB or MFM specialist immediately. Metformin is not a teratogen in the classic sense, but the lack of long-term offspring data is a real limitation. Do not stop or continue without clinician guidance.

Lactation

Metformin transfers into breast milk at low levels. A 2005 pharmacokinetic study found infant exposure through breast milk was approximately 0.28 percent of the weight-adjusted maternal dose, which is generally considered low. LactMed classifies metformin as probably compatible with breastfeeding. Still, if you are breastfeeding and taking metformin off-label for longevity rather than for an active diabetes or PCOS indication, discuss the risk-benefit balance with your prescriber.

Contraception

Metformin is not a teratogen that requires mandatory contraception the way isotretinoin or valproate do. No contraception requirement applies specifically because of metformin. Women with PCOS who resume ovulation on metformin may be at unexpected risk of pregnancy if they assumed they were anovulatory. If you are not trying to conceive and you start metformin for PCOS or longevity, use reliable contraception.

Insurance Coverage: The Honest Breakdown

This is where most longevity content fails women. The short answer is that insurance almost never covers metformin prescribed for longevity, and the workaround costs less than a daily cup of coffee.

What Insurers Require

Commercial health insurance and Medicare Part D cover metformin when the diagnosis code on the prescription is type 2 diabetes (ICD-10 E11.x) or, in many plans, prediabetes (ICD-10 R73.09) or PCOS (ICD-10 E28.2). When a prescriber writes metformin for longevity without one of these qualifying diagnoses, insurers classify it as off-label for a non-covered indication and deny the claim.

The Prediabetes Pathway

The Centers for Disease Control estimates that 96 million American adults have prediabetes, and 80 percent are unaware of it. Many women pursuing longevity use of metformin will, after a fasting glucose or HbA1c test, qualify for a prediabetes diagnosis, and metformin is endorsed for prediabetes by the American Diabetes Association Standards of Care, which recommend metformin for high-risk prediabetes patients, particularly those with BMI <35, under age 60, or with prior gestational diabetes. If you qualify for that diagnosis, your prescriber can write the prescription on-label and insurance may cover it.

What It Costs Out of Pocket

Generic metformin immediate-release is one of the cheapest drugs in the United States. At major pharmacy chains with a GoodRx coupon:

| Dose | Monthly supply | Approximate cash price | |---|---|---| | 500 mg twice daily | 60 tablets | $4, $7 | | 1,000 mg twice daily | 60 tablets | $6, $12 | | 1,500 mg twice daily | 90 tablets (split doses) | $9, $14 |

Metformin extended-release (ER or XR) costs slightly more, roughly $10 to $30 per month out of pocket, and some formulations lost generic availability after a 2020 FDA recall of certain extended-release lots due to NDMA contamination. The FDA's updated list of recalled extended-release metformin lots should be reviewed by your pharmacist before dispensing.

Telehealth Prescribing and Cost Transparency

Many telehealth platforms now offer metformin for metabolic health, PCOS, and longevity-adjacent indications. Consultation fees range from $0 to $150 for the first visit, with follow-up fees of $30 to $75 quarterly. The total annual cost, including visits and drug, typically runs $150 to $400 per year for women paying entirely out of pocket. That is substantially less than branded GLP-1 agonists, which exceed $1,000 per month without insurance.

Who This Makes Sense For (and Who Should Wait)

The following framework is based on available evidence as of mid-2025 and is not a substitute for individualized clinical assessment.

Women for Whom Off-Label Longevity Use Has a Reasonable Evidence Base

• Women aged 40 to 79 with confirmed prediabetes (fasting glucose 100 to 125 mg/dL or HbA1c 5.7 to 6.4 percent) who want both glycemic and potentially longevity-adjacent benefit. This population overlaps with the ADA's on-label recommendation, so coverage is more likely.
• Women with PCOS at any age who already tolerate metformin and whose clinician agrees the metabolic benefits justify continuation beyond active fertility treatment.
• Postmenopausal women with metabolic syndrome features (elevated waist circumference, borderline fasting glucose, elevated triglycerides) who have discussed the unanswered evidence question with a clinician and accept that TAME results are not yet in.

Women for Whom the Evidence Does Not Currently Support Off-Label Use

• Metabolically healthy women under 40 without PCOS, prediabetes, or significant family history of early metabolic disease. The mechanism is plausible, but no trial has tested this group, and potential harms including B12 depletion and GI side effects are real.
• Women actively trying to conceive without a concurrent PCOS or prediabetes indication. Metformin's effects on early embryo development are not fully characterized.
• Women with eGFR <30 mL/min/1.73m2. Metformin is contraindicated due to lactic acidosis risk regardless of indication.
• Women with a history of lactic acidosis, heavy alcohol use, or conditions causing tissue hypoperfusion.

Side Effects Women Should Know About

Most women tolerate metformin well at low starting doses. The most common complaints are GI: nausea, loose stools, and metallic taste, typically worst in the first two to four weeks. Starting at 500 mg once daily with dinner and titrating up over four weeks reduces this substantially.

Two female-specific concerns deserve explicit mention.

Vitamin B12 Depletion

A 2010 trial in Diabetes Care found that long-term metformin use was associated with a 19 percent reduction in serum B12 levels, and B12 deficiency causes peripheral neuropathy that can be misattributed to aging or diabetic neuropathy. Women who are vegan or vegetarian, already at higher baseline risk of B12 deficiency, should have B12 checked at baseline and annually. Supplementation with 1,000 mcg methylcobalamin daily is a low-cost insurance against this.

Lactic Acidosis

Rare but serious. Risk is highest in women with renal impairment, liver disease, or who consume alcohol heavily. The FDA label requires checking renal function before starting and at least annually thereafter. EGFR <30 is a hard contraindication; eGFR 30 to 45 requires dose reduction and closer monitoring.

The B12 and Micronutrient Monitoring Protocol Women Should Follow

If you take metformin off-label for longevity, ask your clinician for a baseline panel and annual repeats covering:

• Serum B12 (or methylmalonic acid if borderline)
• CBC to screen for macrocytic anemia
• Comprehensive metabolic panel including creatinine and eGFR
• HbA1c and fasting glucose (to track whether an on-label indication develops)
• Folate (particularly relevant if you are of reproductive age)

This monitoring protocol costs roughly $50 to $150 per year with discount labs if insurance does not cover it.

Comparing Metformin to Rapamycin and Other Longevity Compounds

Women researching longevity off-label often encounter rapamycin (sirolimus) as an alternative. The comparison matters because the evidence profiles are quite different.

Rapamycin inhibits mTORC1 more directly than metformin and has extended lifespan in mouse models by 9 to 14 percent even when started late in life. However, it carries immunosuppressive effects, potential menstrual cycle disruption, and no completed human longevity RCT. Metformin has decades of human safety data, a known side-effect profile, and costs a fraction of compounded rapamycin, which runs $100 to $400 per month out of pocket.

For women who want a longevity-adjacent intervention with the most human safety data and the lowest cost, metformin sits at one end of that spectrum. For women who want the strongest preclinical signal and are willing to accept a less characterized human safety profile, rapamycin sits at the other. These are different bets, and a clinician familiar with both is worth consulting before making either one.

Practical Steps: Getting Metformin Off-Label for Longevity

1. Get baseline labs. Request fasting glucose, HbA1c, CMP (including creatinine and eGFR), and B12. Many women discover they already qualify for an on-label indication at this step.
2. Find a prescriber willing to discuss off-label use explicitly. Not all clinicians are comfortable with longevity prescribing. A telehealth platform specializing in metabolic or women's health may be more familiar with this conversation.
3. Ask for generic metformin immediate-release. It has the longest safety record and lowest cost. Extended-release may reduce GI side effects but costs more and had recall issues in 2020.
4. Use GoodRx or a pharmacy discount card at the counter. Do not submit to insurance unless you have a qualifying diagnosis, because a denial creates a paper trail that some insurers use to flag future claims.
5. Schedule a follow-up at three months for GI tolerance check and at 12 months for B12 and metabolic labs.
6. Watch for TAME results. The trial's primary outcome data is expected around 2026. That publication will be the most important piece of evidence to date for or against this practice.